AnaSpec Introduces New MMP Recombinant Proteins

Fremont, CA, April 25, 2010 --( AnaSpec has announced the release of three new MMP recombinant proteins, MMP-1, MMP-9 and MMP-12. These proteins, derived from the catalytic domain of the proteins, are supplied as activated proteins (activation by APMA is not necessary). They can be used as positive controls for the SensoLyte® 520 and 490 assays, for western blot, immunoprecipitation, ELISA or zymography.

Matrix metalloproteinases (MMPs) belong to a family of secreted or membrane-associated zinc endopeptidases capable of digesting extracellular matrix components.1-2 MMP-1 (collagenase-1) is involved in tumor development, metastasis and rheumatoid arthritis.3-5 MMP-1 is proposed as a therapeutic target for these diseases. It digests a broad range of substrates, including α-1 antitrypsin, myelin basic protein, collagen I, II, III, VII, VIII, casein, gelatin, and others. 3-5 MMP-9 (92-kDa gelatinase, collagenase-IV) is involved in a number of diseases such as cancer, angiogenesis, alopecia, and metastasis. 6-7 MMP-9 is secreted as zymogen with prodomain, gelatin-binding domain consisting of three contiguous fibronectin type II units, catalytic domain, proline-rich linker region, and C-terminal hemopexin-like domain. It can degrade a variety of substrates, including gelatin, collagens type IV, V, XIV, a2-macroglobulin, elastin, vitronectin, and proteoglycans.1,2,6,7 MMP-12 (macrophage elastase) is involved in smoke-induced emphysema, tumor and other diseases. 8-9 MMP-12 is secreted as a 54-kDa zymogen and becomes the mature 45-kDa active form after proteolytic cleavage. MMP-12 has a broad range of substrates, including α-1 proteinase inhibitor, α-2 antiplasmin, plasminogen activator inhibitor-2, collagen IV, laminin, fibronectin, elastin, but not interstitial collagens.8-9

1. Woessner, J. et al. J. Biol. Chem. 263, 16918 (1988).
2. Woessner, J. FASEB J. 5, 2145 (1991).
3. Goldberg G. I. et al. Ann. N.Y. Acad. Sci. 580, 375 (1990).
4. Stetler-Stevenson, WG. et al. Annu. Rev. Cell Biol. 9, 541(1993).
5. Gravallese, EM. et al. Arthritis Rheum. 34, 1076 (1991).
6. Wilhelm, SM. et al. J. Biol.Chem. 264, 17213 (1989).
7. Fosang, AJ. et al., Biochem.J. 295, 273 (1993).
8. Hautamaki, D. et al. Science 277, 2002 (1997).
9. Dong, Z. et al. Cell 88, 801 (1997).

About AnaSpec

AnaSpec is a leading provider of integrated proteomics solutions to the world’s largest biotech, pharmaceutical, and academic research institutions. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents, and antibodies.

AnaSpec recently joined forces with Eurogentec to provide an even broader spectrum of products and services to serve the worldwide life science community.

For more information visit

About Eurogentec

Eurogentec is a leading global supplier of innovative reagents, kits, specialty products and custom services to scientists in the life science, biotechnology, pharmaceutical and diagnostic markets. Eurogentec provides a wide range of expertize in small- and large-scale DNA, RNA, PCR and qPCR kits, peptide synthesis and antibody supply for research applications. Our ISO13485:2003-certified manufacturing facilities in Belgium provides a wide range of high value oligonucleotide-based components for diagnostic and therapeutic applications. Eurogentec’s Belgium manufacturing facility is complemented by additional production facilities in North America and Japan. Eurogentec is also an experienced Contract Manufacturing Organization (CMO) for Biopharmaceuticals, operating a full-service, state-of-the-art GMP facility in Belgium.

Eurogentec is a privately held company headquartered in Liège, Belgium, with subsidiaries in North America, France, Germany, the UK, the Netherlands and Switzerland and has additional production facilities in North America, Japan and Singapore. Eurogentec employs 400+ people globally.

For more information visit

AnaSpec, Inc.
Ping Yang